|
1
|
Chan KW: Acute lymphoblastic leukemia.
Curr Probl Pediatr Adolesc Health Care. 32:40–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma JJ, Chen Y and Yu L: Research progress
on drug-resistance of acute lymphoblastic leukemia-review. Zhongguo
Shi Yan Xue Ye Xue Za Zhi. 24:261–265. 2016.(In Chinese).
PubMed/NCBI
|
|
3
|
Jing H and Feng R: Research progress on
minimal residual disease in acute leukemia detected by
multiparametric flow cytometry. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
22:847–851. 2014.(In Chinese). PubMed/NCBI
|
|
4
|
Johnson-Arbor K and Dubey R: Doxorubicin.
StatPearls. (Treasure Island, FL). 2019.
|
|
5
|
Mehta-Shah N, Ratner L and Horwitz SM:
Adult T-cell leukemia/lymphoma. J Oncol Pract. 13:487–492. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ballmann C, Denney T, Beyers RJ, Quindry
T, Romero M, Selsby JT and Quindry JC: Long-term dietary quercetin
enrichment as a cardioprotective countermeasure in mdx mice. Exp
Physiol. 102:635–649. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lipshultz SE, Lipsitz SR, Sallan SE,
Dalton VM, Mone SM, Gelber RD and Colan SD: Chronic progressive
cardiac dysfunction years after doxorubicin therapy for childhood
acute lymphoblastic leukemia. J Clin Oncol. 23:2629–2636. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Padron E and Fernandez H: Anthracycline
dose intensification in young adults with acute myeloid leukemia.
Ther Adv Hematol. 3:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Yao J, Han C, Yang J, Chaudhry MT,
Wang S, Liu H and Yin Y: Quercetin, inflammation and immunity.
Nutrients. 8:1672016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Darband SG, Kaviani M, Yousefi B,
Sadighparvar S, Pakdel FG, Attari JA Mohebbi I, Naderi S and
Majidinia M: Quercetin: A functional dietary flavonoid with
potential chemo-preventive properties in colorectal cancer. J Cell
Physiol. 233:6544–6560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Francaux M and Deldicque L: Using
polyphenol derivatives to prevent muscle wasting. Curr Opin Clin
Nutr Metab Care. 21:159–163. 2018.PubMed/NCBI
|
|
12
|
Han Y, Yu H, Wang J, Ren Y, Su X and Shi
Y: Quercetin alleviates myocyte toxic and sensitizes anti-leukemic
effect of Adriamycin. Hematology. 20:276–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alam RT, Zeid EH and Imam TS: Protective
role of quercetin against hematotoxic and immunotoxic effects of
furan in rats. Environ Sci Pollut Res Int. 24:3780–3789. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brito AF, Ribeiro M, Abrantes AM, Pires
AS, Teixo RJ, Tralhão JG and Botelho MF: Quercetin in cancer
treatment, alone or in combination with conventional therapeutics?
Curr Med Chem. 22:3025–3039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamson DW and Brignall MS: Antioxidants
and cancer therapy II: Quick reference guide. Altern Med Rev.
5:152–163. 2000.PubMed/NCBI
|
|
16
|
Chen C, Zhou J and Ji C: Quercetin: A
potential drug to reverse multidrug resistance. Life Sci.
87:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Belli JA and Harris JR: Adriamycin
resistance and radiation response. Int J Radiat Oncol Biol Phys.
5:1231–1234. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Shen H, Tian C, Yu H, Zheng G,
XuFeng R, Ju Z, Xu J, Wang J and Cheng T: Kinetics of normal
hematopoietic stem and progenitor cells in a Notch1-induced
leukemia model. Blood. 114:3783–3792. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao
S, Xu J, Zhu X, Yuan W, Cheng T and Zheng G: Notch1-induced T cell
leukemia can be potentiated by microenvironmental cues in the
spleen. J Hematol Oncol. 7:712014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garnett MJ and McDermott U: The evolving
role of cancer cell line-based screens to define the impact of
cancer genomes on drug response. Curr Opin Genet Dev. 24:114–119.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cappetta D, De Angelis A, Sapio L,
Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S and
Urbanek K: Oxidative stress and cellular response to doxorubicin: A
common factor in the complex milieu of anthracycline
cardiotoxicity. Oxidative medicine and cellular longevity.
2017:15210202017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brown PA, Shah B, Fathi A, Wieduwilt M,
Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, et al:
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version
1.2017. J Natl Compr Canc Netw. 15:1091–1102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HS, Wannatung T, Lee S, Yang WK, Chung
SH, Lim JS, Choe W, Kang I, Kim SS and Ha J: Quercetin enhances
hypoxia-mediated apoptosis via direct inhibition of AMPK activity
in HCT116 colon cancer. Apoptosis. 17:938–949. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maso V, Calgarotto AK, Franchi GC Jr,
Nowill AE, Filho PL, Vassallo J and Saad ST: Multitarget effects of
quercetin in leukemia. Cancer Prev Res (Phila). 7:1240–1250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen Y, Croft KD, Hodgson JM, Kyle R, Lee
IL, Wang Y, Stocker R and Ward NC: Quercetin and its metabolites
improve vessel function by inducing eNOS activity via
phosphorylation of AMPK. Biochem Pharmacol. 84:1036–1044. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rivina L, Davoren M and Schiestl RH:
Radiation-induced myeloid leukemia in murine models. Hum Genomics.
8:132014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Almosailleakh M and Schwaller J: Murine
models of acute myeloid leukaemia. Int J Mol Sci. 20(pii):
E4532019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Segredo MP, Salvadori DM, Rocha NS,
Moretto FC, Correa CR, Camargo EA, de Almeida DC, Reis RA, Freire
CM, Braz MG, et al: Oxidative stress on cardiotoxicity after
treatment with single and multiple doses of doxorubicin. Hum Exp
Toxicol. 33:748–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
